<SEC-DOCUMENT>0001193125-15-192740.txt : 20150519
<SEC-HEADER>0001193125-15-192740.hdr.sgml : 20150519
<ACCEPTANCE-DATETIME>20150519075335
ACCESSION NUMBER:		0001193125-15-192740
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150518
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150519
DATE AS OF CHANGE:		20150519

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Minerva Neurosciences, Inc.
		CENTRAL INDEX KEY:			0001598646
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				260784194
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36517
		FILM NUMBER:		15875044

	BUSINESS ADDRESS:	
		STREET 1:		1601 TRAPELO ROAD
		STREET 2:		SUITE 284
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		617-600-7373

	MAIL ADDRESS:	
		STREET 1:		1601 TRAPELO ROAD
		STREET 2:		SUITE 284
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d928292d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) of the </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): May&nbsp;18, 2015 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Minerva Neurosciences, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>001-36517</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>26-0784194</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of&nbsp;incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>1601 Trapelo Road</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Suite 284</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Waltham,
MA</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>02451</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code): (617)&nbsp;600-7373 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former address, if changed since last report) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.02</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Appointment and Election of Fouzia Laghrissi-Thode, M.D. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;18, 2015, the Board of Directors (the &#147;Board&#148;) of Minerva Neurosciences,&nbsp;Inc. (the &#147;Company&#148;) elected
Fouzia Laghrissi-Thode, M.D. (age 52), as a member of the Board, effective immediately. The Board determined that Dr.&nbsp;Laghrissi-Thode is independent.&nbsp;Dr.&nbsp;Laghrissi-Thode will be a Class&nbsp;II director of the Company and is expected
to stand for re-election at the annual meeting of the stockholders of the Company to be held in 2016.&nbsp;Dr.&nbsp;Laghrissi-Thode has also been appointed to serve as a member of the Audit Committee of the Board, effective immediately. Simultaneous
with Dr.&nbsp;Laghrissi-Thode&#146;s appointment to the Audit Committee of the Board, Francesco de Rubertis, Ph.D. resigned as a member of the Audit Committee of the Board and was appointed as a member of the Nominating and Corporate Governance
Committee of the Board, such resignation and appointment each effective immediately. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Laghrissi-Thode is currently vice president
of the cardiovascular and metabolism therapy area at AstraZeneca and has previously held positions of leadership at Roche, Novartis and Sandoz in a broad range of therapeutic areas, including central nervous system, cardiovascular, metabolic disease
and genito-urinary health. Dr.&nbsp;Laghrissi-Thode holds an M.D. from the University of Tours School of Medicine in France, is board certified in psychiatry and is adjunct professor of psychiatry at the University of Pittsburgh.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the Company&#146;s customary practice, the Company has entered into an indemnification agreement with
Dr.&nbsp;Laghrissi-Thode, which requires the Company to indemnify her against certain liabilities that may arise in connection with her status or service as a director.&nbsp;The indemnification agreement also provides for an advancement of expenses
incurred by Dr.&nbsp;Laghrissi-Thode in connection with any proceeding relating to her status as a director.&nbsp;The foregoing description is qualified in its entirety by the full text of the form of indemnification agreement, which was filed with
the Securities and Exchange Commission (the &#147;SEC&#148;) as Exhibit&nbsp;10.1 to the Company&#146;s Registration Statement on Form&nbsp;S-1 (Registration No.&nbsp;333-195169), and which is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no arrangement or understanding between Dr.&nbsp;Laghrissi-Thode and any other person pursuant to which Dr.&nbsp;Laghrissi-Thode was
selected as a director.&nbsp;Other than as described above, there are no transactions involving Dr.&nbsp;Laghrissi-Thode requiring disclosure under Item&nbsp;404(a)&nbsp;of Regulation S-K of the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;18, 2015, the Company issued a press release relating to the appointment described above, a copy of which is attached as Exhibit
99.1 to this Current Report on Form 8-K and incorporated herein by reference. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release issued by Minerva Neurosciences, Inc., dated May 18, 2015.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"><B>MINERVA NEUROSCIENCES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May&nbsp;19, 2015</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Mark Levine</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Mark Levine</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">Senior Vice President, General Counsel and Secretary</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX OF EXHIBITS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release issued by Minerva Neurosciences, Inc., dated May 18, 2015.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d928292dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g928292g90a88.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&nbsp;18, 2015 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Minerva Neurosciences
Announces Appointment of Dr.&nbsp;Fouzia Laghrissi-Thode to Its Board of Directors </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WALTHAM, Mass.,&nbsp;May 18, 2015</B> &#151;&nbsp;Minerva
Neurosciences, Inc.&nbsp;(Nasdaq:NERV) today announced the appointment of&nbsp;Fouzia Laghrissi-Thode, M.D. to its board of directors, effective immediately. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Dr. Laghrissi-Thode&nbsp;brings extensive experience in global pharmaceutical development to Minerva. Her perspectives and insights spanning commercial
and clinical practice will play a vital role in helping us to build an industry-leading company developing innovative therapies to address a range of unmet needs in central nervous system (CNS) diseases,&#148; said&nbsp;Remy Luthringer, Ph.D.,
president and chief executive officer of Minerva. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Dr. Laghrissi-Thode&#146;s&nbsp;outstanding record of proven success at leading companies in the
pharmaceutical industry has been marked by her ability to advance many strategic and innovative opportunities to bridge science with unmet patient needs and commercial objectives,&#148; said&nbsp;Marc D. Beer, chairman of the board of Minerva. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Laghrissi-Thode&nbsp;has nearly 20 years of experience in the pharmaceutical industry, and has held positions of leadership at AstraZeneca, Roche,
Novartis and Sandoz in a broad range of therapeutic areas, including central nervous system, cardiovascular, metabolic disease and genito-urinary health. She is currently vice president of the cardiovascular and metabolism therapy area at
AstraZeneca. Her business development and licensing accomplishments include demonstrated successes in global product strategy, franchise development and expansion, collaborations, corporate partnerships and joint ventures.&nbsp;Dr.
Laghrissi-Thode&nbsp;holds an M.D. from the&nbsp;University of Tours School of Medicine&nbsp;in&nbsp;France, is board certified in psychiatry and is adjunct professor of psychiatry at the University of&nbsp;Pittsburgh. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About&nbsp;Minerva Neurosciences </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Minerva Neurosciences,
Inc.&nbsp;is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases. Minerva is developing proprietary compounds, including its lead program MIN-101 in
development for the treatment of schizophrenia, MIN-202 in development for primary and comorbid insomnia, MIN-117 in development for the treatment of major depressive disorder and MIN-301 in development for the treatment of Parkinson&#146;s disease.
Minerva&#146;s common stock is listed on the&nbsp;NASDAQ Global Market&nbsp;where it trades under the symbol &#147;NERV&#148;. For more information, please visit:&nbsp;<U>www.minervaneurosciences.com/</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Forward-Looking Safe-Harbor Statement </I></B><I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This&nbsp;press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act
of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management&#146;s expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements
include statements herein with respect to the benefits of and our ability to leverage the proceeds of the private placement and management&#146;s ability to successfully achieve its goals. These forward-looking statements are only predictions and
may differ materially from actual results due to a variety of factors including, without limitation, whether any of our </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
other therapeutic products will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the&nbsp;U.S. Food and Drug
Administration&nbsp;or equivalent foreign regulatory agencies and for which indications; whether any of our therapeutic products will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will
be successful; our ability to achieve the results contemplated by our co-development agreements;&nbsp;management&#146;s ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to
us; and&nbsp;general economic conditions. These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption &#147;Risk Factors&#148; in our filings with
the&nbsp;Securities and Exchange Commission, or&nbsp;SEC, including our Quarterly Report on Form 10-Q for the quarter ended&nbsp;March 31, 2015, as filed with the&nbsp;SEC&nbsp;on&nbsp;May 7, 2015. Copies of reports filed with the&nbsp;SEC&nbsp;are
posted on our website at&nbsp;<U>www.minervaneurosciences.com</U>. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking
statements, except as required by law. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media contact: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bill Berry </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Berry&nbsp;&amp; Company Public Relations </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">212-253-8881 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>bberry@berrypr.com </U></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor contact: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stephanie Ascher </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stern Investor Relations </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">212-362-1200 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>stephanie@sternir.com </U></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g928292g90a88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g928292g90a88.jpg
M_]C_X``02D9)1@`!``$`8`!@``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``@&!@<&!0@'!P<*"0@*#18.#0P,#1L3%!`6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`"\`G`,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/?Z`*&H:O::=M65RTS<)$G+,>W%;4Z,ZFVW<PJXB%+1[]CD
MS\4M)M_$EQI-[$T,<.%^TJ=Z;OX@1UP#QGFL[:Z&<L4H2M-6.VMKF"\MTGMI
MDFA<95T;(/XU)U1DI*Z):!A0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`'/^
M)]2N[.WV64B*X4-+W=%)P"/;((S77A84YSM,X,;5J4X?N_F8GAS1YM1%S?23
M-&Y!2*4C<0YZMSUQ_.NK&55&/LXG%@:#J-U9?+U,R?X-64TBR?VS<AU.<^6I
MSZYKRMCT9X:,U9LX2+4-=\":Y<6<%PT4D+X>,\QR#L<>X[UKHT>.IU,--Q3/
M>-`U%]7T&QU"6-8WN(@[*IX!/I6;T/?I3YX*3ZG$ZO\`$Z;2/%TVDRZ=&;.&
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MO<SU\8>-2X#>"G`S@GS#Q3Y8]S/ZQB/^?9>\6^,[_0-8T[3;'2UO9[U,JIDV
MG=G&!2C%-7+KXB5*2A%7N9Y^(VIZ5=0)XD\-S:?;S-M$ZON`_3^M/D3V9G]<
MG!KVL+(U?$'C*7P_XDTNRFM$;3K_``!<[SE3G!XQ[@_0THQNC6KB'2J1BUH^
MITFHWT6F:;<WTYQ%;QM(WT`J4KZ'5.2A%R?0P_"_BB;6?#,VN:C:I96ZERN'
M+91>K<^^?RJI1L[(PHUW4I^TDK(H^"?'R>+;N\M9+46LL(#QKOSO3.,_4<?G
M3E#E,\-BE7;35CM*S.T\N^(6M2:%XXTJ["[X3:F.>+M)&6.1_4>XK2%UJCRL
M94]G5B^EM?0]%TIK-]*M6L&#6C1@QD=P:F<G*3<MST:2A&"4-BY4FAYU\4?#
ML>I62ZC:[?M]K&6=!]Z2(=3^&<_G6D4[7Z'FXZDIJZW7Y'3^"O\`D2M'_P"O
M9:A[G5AOX,?0\]NM'&O>-_&M@!F1K4/%[.NPC_#\:VO:*//=/VE:K'R_R(+S
MQ-/X@\!:+X>A<G4;R<6DPSR%0CD_7Y?R-"C:39,JSJT8TEN]#:\,VD5A\7M6
MLX%VQ064<:CV"QBIEK!&]"*CBI171?Y"_#W_`)&GQC_UW/\`Z$]$]D&$_B5/
MZ[G,>'/"Y\1>!M2DM1MU.SO6EMV7@G"C*Y]^WOBKE+ED<M&A[6C)K=/0E\3^
M*!XF^'5DTY"ZA:WBQW*=#G:V&Q[_`,\THQY9#KU_;4%?=/4V_BB9Q=>%?LH4
MW`E/E!NA;*8S^.*5/J;XZ]Z=M_\`AC6@N?B6;F(3V.F"'>-Y5N0N><<^E3[A
MLGB[ZI&3\1'O(_'_`(;?3HDEO%4F%)#A6;=P":J'PNYCB^95X<NYF74OB'Q_
MX@'AK5C::=]B?S98U!W-CCY>3G@_KFGI!71E)U<5/V4[*QV7Q(T`:EX+D^SH
M?.T_$T6.N%'S#\OY5G!V9VXREST=.AS'B#Q+-XC\":#IEHV;[5I%AE`/380&
MS]3@U:CRR;.6K6=6C""WD7OB+>0Z#X3T[PM9R+$;D+$S$X"Q+C)/U/\`6E!7
M=S3%R5*E&C'J8>KZIHGA[Q)X>U70M0@N(K:);6Z2)N2@XR?J"?Q`JDFTTS"I
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M48]C5.2<4CFIT91KRJ/9F=HOP_;3/B#=ZVQB-CEI+=`?F5VZY'8#+4W.\;&=
M/"<E=U.G0T=.\-7]I\1]4UZ0Q?8[F$(@#?-D!>HQ_LFDY+E2-(491Q$JCV?_
M``"/PIX7U#1=;\07=T8C%?R[X=C$G&6//''44Y232%0H2ISG)]1_P^\-7_AG
M2[RWOS$7FN#(OEMN&,`>GM2G)2>@\)1E1BU+N<UXS^&-YJ>NOJ&B-`D=Q\TT
M<CE0']1QW_G5QJ65F<V)P4ISYJ?4V_'/A;5]<DT6;2F@$M@Q<F5L#/RX[<_=
MJ822O<VQ5"I4Y7#H5O)^*/\`S]:5_P!\_P#UJ/<%;&=T7M<\,ZGJ?C#P]JR&
M$Q6('VC+8.<Y.!CFDI))HNI1G.K"?89XO\)ZC>Z]IWB#0'BCU*V;$@D;:)%'
M3/'U'T-.,DE9BQ%"<IJI3W1V:@RVX6>,`NN'3.0,CD>]9G;NM3R_P1X,?3?'
MVJ23J3;::2MMNZ'?R"/HOZFMI2O$\O#89PKR;V6QL'P9=:QX]NM8U^&WFTY(
M_+MH-V_(Z#(_,_4U/-:-D;?5I5*SG4VZ%[7/A]H=]HMW;6.F6MM=NA\J5$"E
M6'3GTI*;3U+JX2G*#44DS0\'V6J:9X:MK#5Q&;BWS&K1ON!0?=_3C\*4FF[H
MTP\9PIJ,]T;U2=!RWB7P%HWB17DDB^S7A'^OB`!/^\.C52=CEK86%779]S*\
M+_#R30]*EL;B[1S-*6EEC'+1@_(@ST]3[UI2J*D^9+7H9O#2E!4Y/3KYG:V6
MGVNG0^5:PK&O?'4_4]ZB=251WDSIITH4E:"L6:@U*0U`><T31E6$H1>?O#ID
M?3TK7V>ES#VVMK=1L>H%XYI-BXB#'`)SP?ICM3=.S2!5KIOL27%[]G$GR`[$
M5N3@<G%3&GS6'.KRW&)?F2(%(U9S)Y:[6^5CC.<^G7\J;IV>HE5NM%UMY"O?
M.D3$PX='V/R2J\9SD#IT[4*FF]P=5I;#C=2.RI!&CML#DE\#!Z8..>AI<B6K
M*YVW:*$GOO)$G[OE'5>3QS3C3O84JO+?3L(U\(_(WI\LH)+*>$Q@9Y[<T>SO
M>W0/:VM?J"WKRB,0P@NR;R&;``SBAP2O=@JCE;E0IO&^V?9]B@@*3ECGG\*7
M)[O,'M'S\HZ"[,MS)$4"%<X!/S'!ZXQT^E$H6BF.-2\G$DDE6*6-=G,F>?H,
MU*C=-E2ERM+N5H=322-6:-D/EL[J>JXP?QR#5NDT[&<:R:NT68))I!F6((",
MC#9_`U$DELS2+D]T35)84`%`!0`4`%`$+6L#%28P2K^8#Z-ZU7/)$>SB^GF(
MEI#'N"AMK`@J6)7GKQ3<VP5.*$2R@C1D"DAL9W,2>.G6ASD]1*G%*PYK6%E9
M2G#-O."1AO4>E)3:&Z<6K"?9(1%Y8#`9W9#$'/KGK3YW>X>SC:PC65NRHH0J
M$&T;6(X].*%.2$Z4=$.>TAD#`J1D@D@D'(Z4E-H;IQ8HMXP%!!;`*@L2>#UZ
M_2CF8^1$9L;?RXT5"@C&U=K$$#TR*?M)7N3[*-DET'?9(O-$@WJV`.'(!QTR
M.]'.[6'[-7N(;.(LS#>&.1G<>,]<>E'.]A>SC>Y*T2.RLPR5SCVS4IM%N*>K
M&"T@5E81C*IY8/\`L^E/GEM<GV<4[V\A([2*($)OQP.7)P!T`]*;FWN"IQCL
%3U!9_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
